NuVasive
NuVasive raises $200M Convertible Note at $3.5B valuation
Quick Facts
NuVasive: Convertible Note Funding Round
NuVasive has successfully raised $200M in Convertible Note funding, reaching a valuation of $3.5B.
Company Overview
Minimally disruptive surgical products for spine
Funding Details
The Convertible Note round was led by TPG Capital, with participation from Goldman Sachs.
Company Information
- Headquarters: 7475 Lusk Boulevard, San Diego, CA 92121
- Founded: 1997
- Employees: 2800+
- Category: MedTech
Investment
NuVasive plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- TPG Capital: Verified investor in Convertible Note
- Goldman Sachs: Verified investor in Convertible Note
Key Investors
About the Author
Related Company Reports
Galvenize Therapeutics Raises $100M Series C to Transform MedTech
Galvenize Therapeutics has secured $100M Series C in funding to accelerate growth and innovation in the medtech sector. Medical device company developing pulsed electric field therapies for cardiac ablation and tumor treatment...
Reprieve Cardiovascular Raises $61M Series B to Transform MedTech
Reprieve Cardiovascular has secured $61M Series B in funding to accelerate growth and innovation in the medtech sector. Cardiovascular device company developing personalized heart failure therapies and monitoring solutions...
ViCentra Raises $85M Series D to Transform MedTech
ViCentra has secured $85M Series D in funding to accelerate growth and innovation in the medtech sector. Medical device company developing innovative insulin patch pumps for diabetes management...
